Comparative Pharmacology
Head-to-head clinical analysis: INDICLOR versus SOLARAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDICLOR versus SOLARAZE.
INDICLOR vs SOLARAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
Solaraze (diclofenac sodium) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation and pain. In actinic keratosis, it may also induce apoptosis and decrease keratinocyte proliferation.
INDICLOR is not a recognized drug; no standard dosing available.
Apply 0.5 mL (1 unit dose) topically to actinic keratoses twice daily for 2 to 4 weeks, then 1 week off, repeat for a total of 3 treatment cycles.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10-15 hours) in patients with normal renal function; prolonged in renal impairment (up to 25 hours in severe cases).
Following topical application, the terminal elimination half-life of diclofenac from plasma is approximately 12 hours (range 8-15 hours). This reflects the slow absorption and distribution from the skin depot, with clinical relevance for twice-daily dosing.
Primarily renal excretion (approximately 70% unchanged drug); biliary/fecal excretion accounts for about 10-15% as metabolites.
Solaraze (diclofenac sodium 3% gel) is primarily eliminated via hepatic metabolism followed by renal excretion of metabolites. Approximately 65% of a dose is excreted in urine as conjugated metabolites, with less than 1% as unchanged drug. About 35% is eliminated in feces via biliary excretion of metabolites.
Category C
Category C
NSAID
NSAID